Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy
Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy
复制标题
DOI：
10.1016/s0194-5998(98)70225-6
复制
发表时间：
1998-05-01
影响因子：
3.4
通讯作者：
Wax, MK
中科院分区：
文献类型：
--
作者：
Allen, GC;Tiu, C;Wax, MK
关于顺铂对儿科患者的耳毒性知之甚少。耳声发射测量是一种快速、可重复、客观的听力评估方法。我们检查了过去接触顺铂的儿科患者的瞬态诱发耳声发射是否与听力检查结果相关。 12 名患者参与了该研究（治疗时平均年龄 7.8 岁，平均累积剂量 442.5 mg/mm(2)，平均 7.1 剂量）。 82.6% 的患者保留了 3000 Hz 的听力。在较高频率下，我们注意到显着的感音神经性听力损失：4 kHz 时为 43.5%； 6 kHz 时为 81.0%； 12 名患者中有 11 名在 8 kHz 时可测量到 90.5% 的瞬态诱发耳声发射。中耳疾病导致 3 名患者出现异常耳声发射（1 名患者有积液，2 名患者有明显的中耳负压）。当中耳正常时，瞬态诱发耳声发射再现性和纯音阈值之间存在统计学上显着的相关性（相关系数= -0.69，p = 0.008）。听力损失的增加还与顺铂首次给药年龄较小（p = 0.044）、化疗周期数高（p = 0.042）和高累积剂量（p = 0.042）相关。
Little is known about cisplatin ototoxicity in pediatric patients. Measurement of otoacoustic emissions is a rapid, reproducible, objective method of evaluating hearing. We examined whether transient-evoked otoacoustic emissions in pediatric patients exposed to cisplatin in the past correlated with audiographic findings. Twelve patients were entered into the study (mean age at treatment 7.8 years, mean cumulative dose 442.5 mg/mm(2), mean 7.1 doses). Hearing at 3000 Hz was preserved in 82.6% of patients. In the higher frequencies significant sensorineural hearing loss was noted: 43.5% at 4 kHz; 81.0% at 6 kHz; and 90.5% at 8 kHz, Transient-evoked otoacoustic emissions were measurable in 11 of 12 patients. Middle ear disease accounted for abnormal otoacoustic emission seen in three patients (1 with effusion, 2 with significant negative middle ear pressure). When the middle ear was normal, a statistically significant correlation was seen between the transient-evoked otoacoustic emissions reproducibility and pure-tone threshold (correlation coefficient = -0.69, p = 0.008), Increased hearing loss was also associated with young age at first dose of cisplatin (p = 0.044), high number of chemotherapy cycles (p = 0.042), and high cumulative dose (p = 0.042).